View
3
Download
0
Category
Preview:
Citation preview
Arctic Aurora LifeScience
Capturing the value in healthcare innovation
FUND MANAGEMENTA R C T I C
Arctic Why in Growth certain idramatidriving tGDP an Diseasepopulatitransforresultingprovidinwith! In years. Tare ente Arctic Arctic Alife sciecare spewith higinvestorstrategycomplemcompan An inv
A A
Why st
St
T S
d
sf
c Auror
nvest in he
in healthcais that we aically. Agingthe underlyind future gro
es are primaion, new mermation basg in novel th
ng new solu2014 and 2
The likelihooering the ma
Aurora Li
Aurora LifeSnce compaecialists with scientific rs unique exy is focusedmented by nies.
estment in
Exposure toPotential toA proven inHealthcare A transpare
tart invest
Strong fundtransforminin the last 3The biotechSector rotatdown to verLarge Biotesmall biotecfor free
ra LifeS
ealthcare?
are is one ofas humans lg populationying growth iowth is exp
arily age reledicines are
sed on profoherapeutics
utions that c2015 there wod of continarket backe
feScience
Science is a nies with foth excellentand industrxposure to t
d on reachininvestments
n Arctic A
o the uniqueo extract excnvestment s
is a diversient, establis
ting now?
damentals wg the treatm
3 years h sector is wtion and pory attractiveech index hach with goo
Science
?
f the dominalive longer an, innovationin healthcarected to ex
lated, e.g cae needed. Tound new kns for previoucould transfowere more d
nued succesed with stron
e
specializedocus on Eur
track recorrial competethe growth
ng excess res also in the
Aurora Life
e growth in cess return strategy withfying asset
shed fund st
?
with beginniment of dise
well funded litical camp
e levels as currentlyd pipeline p
e
ating themeand that then and globare. Healthca
xceed globa
ancer and tThe biotechnowledge inusly unmet morm the treadrugs appross for the seng balance
d global hearope and therd from inveence. By ain the bioteeturn from ie larger com
eScience p
the life sciefrom the bi
h thorough din a genera
tructure with
ing of new eeases. This
thanks to repaigns ahea
y (April 2016priced below
es for the fue number ofal economicare already
al GDP grow
to meet the h industry isn biology anmedical neeatment into oved in the ector is highsheets in th
althcare fune US. The testing in thective portfoch and phanvestments
mpanies suc
provides
ence sectorotech sectodue diligencal portfolioh no long lo
era with innhas attract
ecord numbad of US ele
6) lower valw cash and
Arctic Aur
uture. What f elderly incrc growth are
accounts fowth.
demand froright now u
nd related deds. In canca chronic dUS than in
h, new disruhe compani
d investing eam are ex
e public life slio manage
armaceuticas in the biotech as globa
r through a dor ce of invest
ocked in per
ovative proed high inte
ber of IPOs ection have
uation thanBig Pharma
rora LifeSci
we know focreases e the main ffor 10% of g
om a growinundergoing drug developcer, scientis
disease youany of the
uptive technies.
in primarilyxperienced science secment, it offe
al industriesech sector
al pharmace
diversified p
tment oppor
riods
oduct develoerest from in
and capitataken valua
n S&P 500, a pipelines
ience 1
or
forces global
ng a pment, sts are can live
past 15 nologies
y public health ctor and ers . The
eutical
portfolio
rtunities
opment nvestors
l raises ations
many almost
Arctic Aurora LifeScience 2
Arctic Aurora LifeScience Investment strategy – Active Portfolio Management Investing in biotech and drug development in general requires deep understanding of biology as well as the function of the regulatory and commercial part of drug development, i.e clinical studies and the dynamics between smaller biotech companies and the larger pharmaceutical companies funding the later stages of development and thereby contributing to value creation.
Arctic Aurora LifeScience conducts active portfolio management with focus on listed biotech companies supplemented by larger global pharmaceutical companies in both US and EU.
Investment philosophy is to build a portfolio of successful companies in the life science sector, based on a thorough due diligence process. Due diligence is a combination of top down where the therapeutic areas of medical and commercial interest are selected. Bottom up the universe is screened for companies owning leading science within the selected therapeutic areas and a deep analysis of those companies are undertaken with the aim of finding the best investment opportunities.
To maximize risk/reward we only invest in companies with good clinical data. We do not invest in early stage biotech prior to clinical development in patients.
Close contact with management teams is essential The portfolio is constructed in relation to risk and expected return, building a
diversified portfolio of approximately 40-60 holdings. Risks include company specific risks, most importantly drug development risk, liquidity risks and general risks such as currency and political risks. The risk in Arctic Aurora LifeScience will be mitigated by portfolio construction, where company risk and portfolio weight is considered, giving a differentiated exposure. Structure Arctic Aurora LifeScience
UCITS fund targeting USD 500 million Domicile Ireland Investor profile: Family Offices, Institutions and retail Fee structure for founding investors:
Management fee of 1% and performance fee of 10% measured against the MSCI World/Pharma & Life Science Index Total return Net Index
Custodian is BNY Mellon Trust Company (Ireland) Limited Administrator is BNY Mellon Investment Servicing (International) Limited Auditors is Deloitte
A senior founding team with broad experience and excellent track record
Founder and Chief Investment Officer Ulrica Slåne Bjerke has more than 25 years experience from analyzing and investing in the life science sector. Ulrica has an excellent track record in obtaining significant and repeatable high return of investments
Founder Dr Torbjørn Bjerke has had leading positions in the whole chain within drug development, from scientist in international big companies to positions as CSO and CEO for private and public biotech companies taking products to the market
Analyst Daniel Bolanowski is an experienced analyst within the life science and healthcare field
Ac
Ot
T
The
Ulrica’s
A team fromclient suppoOutstandingthe pharmaThe team hindustry as
e Team:
s ROI at AP
m Arctic Funort, compliag Advisory
a and investhas an exten
well as a p
P3:
nd Managemance and risBoard inclutment indusnsive globarofound rela
ment providsk managemuding 6 senistry l network ination to aca
des full fundment or and very
ncluding exeademia
Arctic Aur
d administra
y successfu
ecutives in t
rora LifeSci
ation includi
l individuals
the life scie
ience 3
ing
s from
nce
Arctic Aurrora LifeSciience 4
A R C T I CF U N D M A N A G E M E N T
Arctic Fund Management ASHaakon VII’s gate 5P.O. Box 1833 VikaNO 0123 OSLO, Norway
Tel +47 2101 3100 Fax +47 2101 3036 E-mail: fundinvestor.afm@arctic.com www.arctic.com
Recommended